Attachment
Gates Package, p.244 · gates:exh:00137
Page text: p.244 · original PDF
- Date
- — (unknown precision)
- Type
- attachment · document
- Topics
- Vaccines
Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership
Christopher Austin, M.D.
Director, National Center for Advancing Translational Sciences
NIH
Stephane Bancel, M.S., M.B.A.
Chief Executive Officer
Moderna
Kara Carter, Ph.D.
Senior Vice President, Discovery Biology
Dewpoint Therapeutics
Marco Cavaleri, Ph.D.
Head, Biological Health Threats and Vaccines Strategy
European Medicines Agency
Tomas Cihlar, Ph.D.
Vice President and Head of Virology
Gilead Sciences, Inc.
Francis Collins, M.D., Ph.D.
Director
NIH
Christine Colvis, Ph.D.
Director, Drug Development Partnership Programs
National Center for Advancing Translational Sciences, NIH
Lawrence Corey, M.D.
Professor, Departments of Laboratory Medicine & Medicine
Member, Division of Vaccine & Infectious Disease (VIDD), Clinical Research, & Public Health Sciences
President & Director Emeritus
Fred Hutchinson Cancer Research Center
Elizabeth Desrosiers, M.S., P.M.P.
Executive Director, Clinical Sciences and Study Management
Merck & Co., Inc.
Gary Disbrow, Ph.D.
Director
Biomedical Advanced Research and Development Authority
Mikael Dolsten, M.D., Ph.D.
Chief Scientific Officer and President, Worldwide Research, Development and Medical
Pfizer
Ken Duncan, Ph.D.
Deputy Director, Discovery -- Therapeutics